Home World News FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC World News FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 353 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR How International Collaboration Has Helped Improve Cancer Care in Nepal April 8, 2021 Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Woman Showed Up To Their Wedding And Stole All Their Gifts.... March 11, 2019 Load more HOT NEWS Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer Building a Balanced Breakfast UN Pandemic Declaration Reflects Key ESMO Priorities FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer...
